Cite
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
MLA
Fischer, Kirsten, et al. “Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.” The New England Journal of Medicine, vol. 380, no. 23, June 2019, pp. 2225–36. EBSCOhost, https://doi.org/10.1056/NEJMoa1815281.
APA
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.-M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Le Dû, K., Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., … Hallek, M. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. The New England Journal of Medicine, 380(23), 2225–2236. https://doi.org/10.1056/NEJMoa1815281
Chicago
Fischer, Kirsten, Othman Al-Sawaf, Jasmin Bahlo, Anna-Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, et al. 2019. “Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.” The New England Journal of Medicine 380 (23): 2225–36. doi:10.1056/NEJMoa1815281.